Status:
UNKNOWN
The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Sepsis
Lead Sponsor:
Jingyuan,Xu
Conditions:
Sepsis
Eligibility:
All Genders
18-80 years
Brief Summary
To observe the changes of plasma hepatocyte growth factor and soluble receptor s-Met levels in patients with sepsis, and to explore its clinical significance.
Detailed Description
90 patients who diagnosed as sepsis were included in this study. Then keep blood samples from these patients in the first day, the third day, detect the hepatocyte growth factor and soluble receptor s...
Eligibility Criteria
Inclusion
- Patients admitted to ICU diagnosed of sepsis(sepsis3.0 criteria)
- Patients signing informed consent
Exclusion
- Age is less than 18 years old or more than 80 years old
- Pregnant women
- Patients with tumor、hepatitis、liver cirrhosis、acute myocardial infarction、chronic renal tubular nephritis、interstitial pneumonia、acute pancreatitis、systemic lupus erythenatosus、ulcerative colitis、crohn's disease、HELLP syndrome
- Prothrombin time is extension in patients with after liver transplantation
- Patients with chronic renal failure
- Patients after kidney transplantation
Key Trial Info
Start Date :
November 9 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2018
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT03340649
Start Date
November 9 2017
End Date
March 1 2018
Last Update
November 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongda Hospital
Nanjing, Jiangsu, China, 210000